'Healthy enough to contest': Malegaon terror victim's father urge NIA to bar Sadhvi

Agencies
April 18, 2019

Mumbai, Apr 18: An application has been filed before the NIA court here against Malegaon blast accused Sadhvi Pragya Thakur, seeking a bar on her contesting the Lok Sabha poll.

The BJP has declared her candidature from Bhopal seat in Madhya Pradesh.

The applicant has questioned Thakur’s candidature citing that she had got bail on the ground of her poor health, but she is “healthy enough to fight elections.”

“That intervener would further submit that Sadhvi Pragya Thakur got bail on health ground but clearly healthy enough to fight elections in the crippling summer heat which means she has misguided the court,” says applicant Sayyed Bilal in his petition, filed in the NIA court on Thursday.

NIA will file its reply on April 23 when the court is also likely to hear the petition.

Nisar Ahmed Sayyed Bilal lost his son Sayyed Azhar Nisar Ahmed on the spot in Malegaon blast that took place on September 29, 2008.

The applicant states that “he came to know by electronic, print and social media that Sadhvi Pragya Thakur has joined the BJP and is going to contest parliamentary elections from Bhopal seat.”

The petitioner has submitted that Thakur was “enlarged on conditional bail and she is not attending hearing of this court on the pretext that she is unwell and she is a ‘breast cancer patient.’ But on the contrary, she has been seen participating in various programmes and giving objectionable and instigating speeches since her release from the jail.”

Thakur has “flayed her duty to the court under false pretense but has submitted herself to the duty of being a parliamentarian. Sadhvi Pragya Thakur has taken a casual outlook to the trial and it casts serious doubt on her non-availability for the trial and the reasons so told.”

The petitioner has further submitted that “during bail hearing in the Bombay High Court Sadhvi Pragya Thakur had filed written statement in support of her health and claimed that she cannot even walk without support, her contention and the High Court’s observations are being reproduced here for kind perusal of this court.”

“Sadhvi Pragya Thakur got bail on health ground but is clearly healthy enough to fight elections in the crippling summer heat which means she has misguided the court,” applicant Sayyed Bilal said in the application.

“Sadhvi Pragya Thakur may be asked to attend court proceeding here in Mumbai and is barred to contest the election as trial is still in progress and the petition of cancellation of bail is sub-judice before the Supreme Court,” the application added.

Thakur is among seven accused facing trial in Malegaon blast case, in which six people were killed and a dozen others were injured when a bomb placed on a motorcycle exploded in Maharashtra’s Malegaon on September 29, 2008.

Polling in Madhya Pradesh will be held in the last four phases of elections, ending on May 19. The counting of votes will take place on May 23.

Comments

MR
 - 
Friday, 19 Apr 2019

Cancer may be another cooked up lies by Sadvi Pradvi thakur and her BJP lawyer

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 11,2020

New Delhi, Mar 11: According to the Union health ministry, there are 62 confirmed cases of coronavirus in the country.

The Delhi High Court Wednesday sought the stand of the Centre and the Delhi government on a PIL seeking proper and adequate measures to combat coronavirus.

A bench of Chief Justice D N Patel and Justice C Hari Shankar issued notice to the Ministry of Health and the Delhi government seeking their replies on the public interest litigation (PIL) filed by an advocate.

The petition, by lawyer Triveni Potekar, seeks directions to the Centre and the Delhi government to make available important and relevant information on access to and availability of medical facilities for testing and treatment for the coronavirus disease.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 4,2020

Beijing/Zurich, Mar 4: China has approved the use of Swiss drugmaker Roche's anti-inflammation drug Actemra for patients who develop severe complications from the coronavirus as it urgently hunts for new ways to combat the deadly infection that is spreading worldwide.

China is hoping that some older drugs could stop severe cytokine release syndrome (CRS), or cytokine storms, an overreaction of the immune system which is considered a major factor behind catastrophic organ failure and death in some coronavirus patients.

Actemra, a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA), inhibits high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

China's National Health Commission said in treatment guidelines published online on Wednesday that Actemra can now be used to treat coronavirus patients with serious lung damage and high IL-6 levels.

Separately, researchers in the country are testing Actemra, known generically as tocilizumab, in a clinical trial expected to include 188 coronavirus patients and running until May 10.

Roche, which donated 14 million yuan ($2.02 million) worth of Actemra during February, said the trial was initiated independently by a third party with the aim of exploring the efficacy and safety of the drug in coronavirus patients with CRS.

It added that there was currently no published clinical trial data on the drug's safety or efficacy against the virus.

More than 3,000 people have died and 93,000 have been infected by the novel coronavirus thought to have originated in Wuhan, China, before spreading to around 90 countries including the United States, Italy, Switzerland, France and Germany.

The Swiss company, for which China is its No. 2 market behind the United States, also makes diagnostic gear to detect the coronavirus.

Since Actemra's approval a decade ago, it has become a go-to drug against other inflammatory conditions, including cytokine storms in cancer patients receiving cell therapies from Novartis and Gilead Sciences.

In 2012 it helped save the life of a young U.S. girl, the first child to be treated for leukaemia with Novatis' Kymriah, from a post-treatment rush of IL-6.

Priced at between $20-30,000 annually for RA according to SSR Health, Roche's medicine is also used for rare juvenile arthritis and giant cell arteritis, or inflammation of the blood vessels.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
March 6,2020

Beijing, Mar 6: World health officials have warned that countries are not taking the coronavirus crisis seriously enough, as outbreaks surged across Europe and in the United States where medical workers sounded warnings over a "disturbing" lack of hospital preparedness.

The World Health Organization warned Thursday that a "long list" of countries were not showing "the level of political commitment" needed to "match the level of the threat we all face".

"This is not a drill," WHO chief Tedros Adhanom Ghebreyesus told reporters.

"This epidemic is a threat for every country, rich and poor."

Tedros called on the heads of government in every country to take charge of the response and "coordinate all sectors", rather than leaving it to health ministries.

What is needed, he said, is "aggressive preparedness."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.